Ask About Your Case
Actos Information
- Actos Attorneys
- June 2011 Bladder Cancer Warnings
- Actos May Cause Bladder Cancer
- What is Bladder Cancer
- Types of Bladder Tumors
- Is Actos Still On The Market?
- Actos Report
Drug Alerts
- Actos & Bladder Cancer
- Fixodent Zinc Poisoning
- NuvaRing
- Topamax
- SSRI Birth Defects
- Yaz & Yasmin Recall
- Zithromax
Recently Added
Is Actos Still On The Market?
In June 2011, the European Medicines Agency (EMA) was informed by the French Medicines Agency of its decision to suspend Actos-related medicines in France. Their reasoning for taking Actos off the market was a prudent wait-and-see outcome of the ongoing European review of some anti diabetic medicine risks and benefits.
Back in September 2010, the U.S. FDA announced it was reviewing data from an ongoing 10-year study of Actos (pioglitazone) and the risk of bladder cancer. FDA completed its review of five-year results, which revealed that although there was no overall increased risk of bladder cancer from Actos, an increased risk was found among patients who had used Actos the longest (for more than 2 years) and at the highest doses.
Then nine months later in June 2011, the FDA informed the public about a possible increased bladder cancer risk when using Actos for more than one year. Did they take Actos off the market like the European and French medical agencies? No.
Instead information about this bladder cancer risk would be added to the Warnings and Precautions section of the label for medicines containing Actos. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer. Who can read that tiny font anyway?
You live in the United States and take Actos for type 2 diabetes. Are you at risk for developing bladder cancer?